Abbott Laboratories (NYSE:ABT) Updates Q1 2025 Earnings Guidance

Abbott Laboratories (NYSE:ABT) updated its first quarter 2025 earnings guidance on Wednesday. The company provided EPS guidance of 1.050-1.090 for the period, compared to the consensus EPS estimate of 1.120. The company issued revenue guidance of -. Abbott Laboratories also updated its FY 2025 guidance to 5.050-5.250 EPS.

Abbott Laboratories Stock Performance

Abbott Laboratories stock opened at $123.17 on Friday. The stock has a fifty day moving average price of $114.91 and a 200 day moving average price of $113.08. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. Abbott Laboratories has a 52 week low of $99.71 and a 52 week high of $123.23. The firm has a market capitalization of $213.62 billion, a P/E ratio of 37.44, a PEG ratio of 2.50 and a beta of 0.73.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.34. Abbott Laboratories had a net margin of 13.99% and a return on equity of 20.18%. The firm had revenue of $10.97 billion during the quarter, compared to the consensus estimate of $11,029,400 billion. During the same period in the previous year, the firm earned $1.19 earnings per share. Abbott Laboratories’s revenue was up 7.2% compared to the same quarter last year. Equities research analysts anticipate that Abbott Laboratories will post 4.67 earnings per share for the current year.

Abbott Laboratories Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Wednesday, January 15th will be paid a dividend of $0.59 per share. The ex-dividend date of this dividend is Wednesday, January 15th. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.55. This represents a $2.36 annualized dividend and a yield of 1.92%. Abbott Laboratories’s dividend payout ratio is currently 30.85%.

Analyst Upgrades and Downgrades

ABT has been the subject of a number of research analyst reports. Stifel Nicolaus increased their target price on shares of Abbott Laboratories from $130.00 to $135.00 and gave the stock a “buy” rating in a research report on Thursday. Mizuho lifted their target price on shares of Abbott Laboratories from $115.00 to $130.00 and gave the company a “neutral” rating in a report on Thursday, October 17th. Morgan Stanley raised their price objective on Abbott Laboratories from $107.00 to $117.00 and gave the company an “equal weight” rating in a research report on Thursday, October 17th. Sanford C. Bernstein upped their target price on Abbott Laboratories from $133.00 to $138.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Finally, Wells Fargo & Company boosted their price target on Abbott Laboratories from $133.00 to $136.00 and gave the stock an “overweight” rating in a research report on Thursday. Four investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $132.50.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.